BioNxt Solutions Inc.

BioNxt Solutions Announces Closing of Shares for Debt Settlement

Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt

BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase

Bionxt Solutions Provides Bi-Weekly MCTO Status Report

BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement

BioNxt Solutions Announces Change of Directors

XPhyto Therapeutics says director and founder Professor Dr Raimar Loebenberg receives leadership award from Canadian Society for Pharmaceutical Science

XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head

XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year

XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds

XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions

XPhyto Therapeutics realizing 'significant synergies' after integration of 3a-diagnostics GmbH

XPhyto Therapeutics announces appointment of Drahoslav Zdarek as the company's head of sales, Europe

Xphyto Therapeutics makes key appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19

Xphyto Therapeutics makes appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19

XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight

XPhyto epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips

XPhyto Therapeutics completes strategic acquisition of 3a-diagnostics GmbH

XPhyto Therapeutics closes its private placements for gross proceeds of C$7M